Medical/Pharmaceuticals
COLOPLAST SINGAPORE LAUNCHES SENSURA MIO(R), A PRODUCT MADE WITH THE LATEST TECHNOLOGY FOR OSTOMY AND STOMA CARE
* SenSura® Mio features BodyFit technology, an elastic adhesive technology fit for all peristomal body profiles. SINGAPORE, Feb. 9, 2022 /PRNewswire/ -- Coloplast, one of the world's leading manufacturers of stoma care products launches its latest product innovation, the SenSura®Mio in Singapor...
2022-02-09 12:44
2922
Luye Pharma Grants Laboratorio LIBRA Exclusive Marketing Rights for Seroquel and Seroquel XR in Chile
SHANGHAI, Feb. 9, 2022 /PRNewswire/ -- Luye Pharma Group announced today that it has entered into an agreement with Laboratorio LIBRA, under which the company grants Laboratorio LIBRA the exclusive rights to market its innovative CNS (central nervous system) drugs Seroquel (quetiapine fumarate, i...
2022-02-09 11:57
2710
CStone announced new drug approval of China's first IDH1 inhibitor TIBSOVO® (ivosidenib tablets) as a new precision therapy for patients with acute myeloid leukemia
* TIBSOVO®, a first-in-class drug, is approved for adult patients with relapsed/refractory acute myeloid leukemia (R/R AML) who have a susceptible IDH1 mutation * Clinical study data showed that TIBSOVO® had robust clinical efficacy and a well-tolerated and manageable safety profile in Chines...
2022-02-09 11:53
5539
Bugworks Research Inc. secures US$18M Series B1 Funding from Reputed Global Investor Syndicate (The EU, UK, Japan, South Africa & India), led by Lightrock India
This Funding will advance highly differentiated assets in the dual areas of Antimicrobial Resistance (AMR) and Immuno-Oncology (IO) BANGALORE, India, SARATOGA, Calif. and ADELAIDE, Australia, Feb. 9, 2022 /PRNewswire/ -- Bugworks Research, a clinical stage multi-indication therapeutics company, ...
2022-02-09 10:00
11257
Bactiguard presents focused growth strategy and sets new long-term financial targets
STOCKHOLM, Feb. 9, 2022 /PRNewswire/ -- Bactiguard presents new long-term financial targets in connection with the year-end report for 2021. The new financial targets relate to growth and profitability, with annual revenues of at least1 billion SEK and annual EBITDA of at least 400 million SEK in...
2022-02-09 07:27
2720
First Proton Therapy Treatment Delivered in Southeast Asia at Her Royal Highness Princess Maha Chakri Sirindhorn Proton Center, Thailand
BANGKOK, Feb. 9, 2022 /PRNewswire/ -- Varian, a Siemens Healthineers company, today announced that Her Royal Highness Princess Maha Chakri Sirindhorn Proton Center has begun treating patients with its new Varian ProBeam® proton therapy system, the first of its kind inThailand and Southeast Asia. ...
2022-02-09 05:15
5759
Bactiguard and Zimmer Biomet expand global license partnership
STOCKHOLM, Feb. 9, 2022 /PRNewswire/ -- Bactiguard and Zimmer Biomet have today agreed to expand the global license partnership, that was initiated in 2019, to cover multiple product segments. The extended exclusive license agreement covers implants for joint reconstruction (hips and knees), spo...
2022-02-09 04:10
2353
Cambrex Recognized with 2022 CMO Leadership Awards for the 8th Consecutive Year
EAST RUTHERFORD, N.J., Feb. 8, 2022 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), announced today that it has been recognized by the annual CMO (Contract Manufacturing Organization) Leadership Awards in the categories of Quality and Service....
2022-02-08 22:30
3984
WuXi Biologics Statement
SHANGHAI, Feb. 8, 2022 /PRNewswire/ -- We have been made aware of a recent U.S. Commerce Department announcement that two WuXi Biologics (Cayman) subsidiaries inShanghai and Wuxi will be added to the department's "Unverified List" (UVL) on February 8, 2022. We understand that the reason for this a...
2022-02-08 11:08
4229
Singapore-Johor VTL resumes with COVID-19 test results issued by Jebhealth
SINGAPORE, Feb. 8, 2022 /PRNewswire/ -- With the resumption of the land VTL betweenSingapore and Johor Bahru on Jan 21, about 2,000 travellers are expected to cross the causeway each day, in hope that we can eventually scale up to the normal 300,000 daily commutes. Many would be meeting their lov...
2022-02-08 07:00
4451
Covaris AFA-energetics™ Enables True Automated Total Nucleic Acid Extraction and Purification Workflows from FFPE Tissues
A fully automated, high-throughput deparaffinization and total Nucleic Acids extraction and purification kit for FFPE samples WOBURN, Mass., Feb. 7, 2022 /PRNewswire/ -- Covaris, LLC ("Covaris" or "the Company"), a manufacturer of advanced tools enabling life science innovations, announced the l...
2022-02-07 23:00
3947
Ascletis Announces Positive Data of Oral Double Prodrug ASC10 and Its Antiviral Nucleoside Analog ASC10-A Against Omicron Variant
* ASC10-A demonstrated strong in vitro antiviral activity against multiple SARS-CoV-2 virus variants including Omicron * By applying a double prodrug strategy, ASC10's permeability in Caco-2 cells and ASC10's oral bioavailability in monkeys were 3.2-fold and 2.3-fold of Molnupiravir, respecti...
2022-02-07 19:00
4554
Clarivate Identifies Seven Medtech Trends to Watch in 2022
LONDON, Feb. 7, 2022 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today released a new report,Outlook on the Medtech Industry: Seven Areas to Watch. The report analyzes seven factors that Clarivate ...
2022-02-07 16:00
2656
Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule CD73 Inhibitor ATG-037
SHANGHAI and HONG KONG, Feb. 7, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and o...
2022-02-07 08:30
4135
The one-component Sputnik Light vaccine has been authorized in India; over 2.5 billion people live in countries that approved Sputnik Light as a standalone vaccine and a universal booster
Sputnik Light will be an important part of India's vaccination program and the fight against mutations of COVID, including Omicron. Sputnik Light has been authorized in more than 30 countries with total population of over 2.5 billion people. MOSCOW, Feb. 7, 2022 /PRNewswire/ -- The Russian Dir...
2022-02-07 08:18
5407
Everest Medicines Announces First Drug Approval of Trodelvy® in Singapore for Second-Line Metastatic Triple-Negative Breast Cancer
SHANGHAI, Feb. 7, 2022 /PRNewswire/ -- Everest Medicines
2022-02-07 08:00
5562
Ascletis Announces U.S. IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors
* The objectives of the U.S. Phase I trial are to find a recommended Phase II dose and obtain preliminary efficacy in patients with advanced solid tumors * The first U.S. patient is expected to be dosed in the first half of 2022 * ASC61 shows significant antitumor efficacy as a single agent i...
2022-02-06 18:30
5469
Vitro S.A. sells Cytognos to BD to prioritize the market launch of their new and disruptive Molecular Biology and Anatomic Pathology diagnostic platforms
Cytognos divestment is a first strategic step aimed at positioning Vitro as a
new worldwide diagnostic player in their key market segments
SEVILLE, Spain, Feb. 4, 2022 /PRNewswire/ -- Vitro S.A, (www.vitro.bio
2022-02-04 17:23
5196
Invitation to the presentation of Elekta's third quarter 2021/22
STOCKHOLM, Feb. 4, 2022 /PRNewswire/ -- Elekta (EKTA-B.ST) invites analysts and investors to a presentation of the third quarter 2021/22 at10:00 a.m. CET on February 24. The interim report for the third quarter will be published at 7:30 a.m. CET on the same day. The company's development will be...
2022-02-04 15:57
4262
Nanoform signs GMP manufacturing program with TargTex following formulation success
HELSINKI, Feb. 4, 2022 /PRNewswire/ -- Nanoform, an innovative nanoparticle medicine enabling company, today announced it has signed a GMP1 manufacturing program (clinical development) to enhance TargTex's Glioblastoma multiforme drug candidate. The program starts with a PoP (Proof of Process) ph...
2022-02-04 15:54
3529
Week's Top Stories
Most Reposted
Carro secures strategic investment from Orico
[Picked up by 297 media titles]
2026-09-18 16:29CityUHK and University of Cambridge establish Centre for Advanced and Smart Manufacturing to shape Hong Kong's Industry 5.0 future
[Picked up by 291 media titles]
2026-09-22 18:37
Agoda Releases AI Developer Report 2026: Agentic AI Adoption Outpaces Enterprise Readiness Across Southeast Asia and India
[Picked up by 291 media titles]
2026-09-24 10:30
CGS International Convenes China-ASEAN Business Leaders Summit to Deepen Capital Connectivity Across the Corridor
[Picked up by 277 media titles]
2026-09-23 09:00
01F Group Announces Investment in DANA, Indonesia's Leading Digital Financial Company, Reinforcing Long-Term Confidence in Asia's Fintech Opportunity
[Picked up by 275 media titles]
2026-09-21 08:00Most Read
COSRX Brings Its 5 Peptide Lip Collection to Ulta Beauty Stores Offline
2026-09-18 22:00
11815
Sea, Gardens, Lawns and Hearths: Life Abroad Across Noah's N+ Club Network
2026-09-18 23:04
8444
Carro secures strategic investment from Orico
2026-09-18 16:29
7805
